Institut Curie – Site Paris

26 Rue D Ulm, Paris, 75005, France

Neoplasms and Oncology Research at Institut Curie – Site Paris

This research site focuses on cancer studies across several neoplastic diseases, with trials aimed at improving treatment outcomes, testing new anti-cancer combinations, and refining supportive approaches for patients with advanced or hard-to-treat tumors.

Studies in breast neoplasms are exploring new treatment strategies for advanced disease, including hormone receptor-positive and HER2-negative cancers.
Research in non-small cell lung cancer is evaluating novel therapy combinations for KRAS G12C-mutant tumors that are either resected or unresectable.
Trials in Ewing sarcoma are assessing ways to improve outcomes for newly diagnosed metastatic disease, including better use of chemotherapy and radiotherapy.

Overall, the clinical research program at Institut Curie is centered on finding more effective and better-tolerated treatments for aggressive cancers, while also examining how treatment selection can improve outcomes in metastatic disease and after surgery.

Phase 2 Study of Rinatabart Sesutecan with PEGFILGRASTIM in Adults with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting

2 1 1 1
Investigated drugs:
- HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
+2
A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Recruiting

2 1 1 1
Investigated drugs:
- Pembrolizumab
- Petosemtamab
Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Recruiting

3 1 1 1
Investigated diseases:
- Non-small cell lung cancer
Investigated drugs:
+11
Comparing AZD5335 with Mirvetuximab Soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Recruiting

3 1 1 1
Investigated drugs:
+4
A study of YL201 and atezolizumab for patients with advanced solid tumors

Recruiting

1 1 1 1
Investigated diseases:
- Neoplasm malignant
Investigated drugs:
- YL201
- Atezolizumab
+2
A Study of Linvoseltamab in Adult Patients with High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Recruiting

2 1 1 1
Investigated drugs:
A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Recruiting

3 1 1 1
Investigated drugs:
+10
A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread

Recruiting

3 1 1
Investigated drugs:
- Darovasertib
+4
Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Recruiting

3 1 1 1
Investigated diseases:
- Squamous cell carcinoma of head and neck
Investigated drugs:
A Study of Mirvetuximab Soravtansine, Carboplatin, and Bevacizumab in Adults with Ovarian Cancer

Recruiting

2 1 1 1
Investigated drugs: